Physician profile
John B Cleek
NPI 1750301404
$136,431.24
in general payments reported to CMS, 2019-2025
18 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $80.91 · 2021: $313 · 2022: $24K · 2023: $11K · 2024: $63K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Travel and Lodging: $11K · Food and Beverage: $3,688 · Consulting Fee: $3,150 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,295.89 |
| Travel and Lodging | $10,706.42 |
| Food and Beverage | $3,687.92 |
| Consulting Fee | $3,150.00 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70,830.35 | 2022-2025 | Zepbound, Mounjaro, Taltz |
| Novo Nordisk INC | $62,836.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Eli Lilly and Company | $1,750.00 | 2025 | |
| Tactile Systems Technology INC | $264.96 | 2023 | Entre Plus, Flexitouch Plus |
| Currax Pharmaceuticals LLC | $163.62 | 2020-2024 | Contrave |
| Rhythm Pharmaceuticals, INC. | $123.16 | 2022-2024 | Imcivree, Imcivree |
| Dexcom, INC. | $97.45 | 2023-2024 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $94.57 | 2022-2023 | Hetlioz |
| Novartis Pharmaceuticals Corporation | $58.86 | 2023 | |
| Amgen INC. | $53.64 | 2023-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $42.95 | 2023 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $18.81 | 2024 | Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.64 | 2022 | |
| Endo Pharmaceuticals INC. | $18.07 | 2019 | |
| Sanofi Pasteur INC. | $17.59 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.50 | 2023 | Quviviq |
| Teleflex LLC | $14.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.86 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cleek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.